Drug use survey for LIXIANA

Drug use survey for LIXIANA - Drug use survey for LIXIANA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008092

Enrollment

2000

Registered

2012-06-04

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of venous thromboembolism in patients who have undergone total knee arthroplasty (TKA) or total hip arthroplasty (THA), or hip fracture surgery (HFS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were administrated LIXIANA for the first time after undergoing TKA, THA, and HFS.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety -frequency of adverse drug reactions -frequency of severe adverse events -frequency of bleeding events Efficacy -frequency of venous thromboembolism Special population -safety and efficacy in patients with hepatic disease, renal disease, and elderly	—

Countries

Japan

Contacts

Public ContactChikada Shuichi

DAIICHI SANKYO COMPANY, LIMITED Pharmacovigilance Department

chikada.shuichi.ic@daiichisankyo.co.jp+81-3-6225-1044

Outcome results